Endurance time is the most responsive exercise measurement in idiopathic pulmonary fibrosis

Respiratory Care

Volumn 59, Issue 7, 2014, Pages 1108-1115

  Arizono, Shinichi ^a,c,d   Taniguchi, Hiroyuki ^b   Sakamoto, Koji ^e   Kondoh, Yasuhiro ^b   Kimura, Tomoki ^b   Kataoka, Kensuke ^b   Ogawa, Tomoya ^a   Watanabe, Fumiko ^a   Nishiyama, Osamu ^f   Nishimura, Koichi ^g   Kozu, Ryo ^h   Tabira, Kazuyuki ^c  

^a Department of Rehabilitation ^*  (Japan)

^b TOSEI GENERAL HOSPITAL   (Japan)

^c KIO UNIVERSITY   (Japan)

^d SEIREI CHRISTOPHER UNIVERSITY   (Japan)

^e NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^f KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^g NATIONAL CENTER FOR GERIATRICS AND GERONTOLOGY   (Japan)

^h NAGASAKI UNIVERSITY HOSPITAL   (Japan)

Author keywords

Endurance time; Exercise capacity; Idiopathic pulmonary fibrosis; Pulmonary rehabilitation; Responsiveness

Indexed keywords

CYCLOSPORIN; PREDNISOLONE;

AGED; AIRWAY PRESSURE METER; ARTICLE; CONTROLLED STUDY; ENDURANCE TIME; ENDURANCE TRAINING; FEMALE; FIBROSING ALVEOLITIS; HUMAN; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; MUSCLE STRENGTH; OBSERVATIONAL STUDY; OXYGEN CONSUMPTION; PEAK WORK RATE; PHYSICAL CAPACITY; PROSPECTIVE STUDY; PULMONARY REHABILITATION; PULSE OXIMETRY; SPIROMETRY; VITAL CAPACITY; WALKING; EXERCISE TEST; EXERCISE TOLERANCE; IDIOPATHIC PULMONARY FIBROSIS; KINESIOTHERAPY; MIDDLE AGED; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PHYSIOLOGY; TIME;

AGED; EXERCISE TEST; EXERCISE THERAPY; EXERCISE TOLERANCE; FEMALE; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; MALE; MIDDLE AGED; MUSCLE STRENGTH; OUTCOME ASSESSMENT (HEALTH CARE); PROSPECTIVE STUDIES; SPIROMETRY; TIME FACTORS;

EID: 84923272821     PISSN: 00201324     EISSN: 19433654     Source Type: Journal    
DOI: 10.4187/respcare.02674     Document Type: Article

References (30)

1. Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011; 183(6): 788-824.
2. Eaton T, Young P, Milne D, Wells AU. Six-minute walk, maximal exercise tests: reproducibility in fibrotic interstitial pneumonia. Am J Respir Crit Care Med 2005; 171 (10): 1150-1157.
3. Nishiyama O, Taniguchi H, Kondoh Y, Kimura T, Ogawa T, Wa-tanabe F, Arizono S. Quadriceps weakness is related to exercise capacity in idiopathic pulmonary fibrosis. Chest 2005; 127(6): 2028-2033.
4. Lederer DJ, Arcasoy SM, Wilt JS, D'Ovidio F, Sonett JR, Kawut SM. Six-minute-walk distance predicts waiting list survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2006; 174(6): 659-664.
5. du Bois RM, Weycker D, Albera C, Bradford WZ, Costabel U, Kartashov A, et al. Six-minute-walk test in idiopathic pulmonary fibrosis: test validation and minimal clinically important difference. Am J Respir Crit Care Med 2011; 183(9): 1231-1237.
6. Idiopathic Pulmonary Fibrosis Clinical Research Network, Zisman DA, Schwarz M, Anstrom KJ, Collard HR, Flaherty KR, Hunning-hake GW. A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis. N Engl J Med 2010; 363(7): 620-628.
7. King TE Jr, Behr J, Brown KK, du Bois RM, Lancaster L, de Andrade JA, et al. BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2008; 177(1): 75-81.
8. Nishiyama O, Kondoh Y, Kimura T, Kato K, Kataoka K, Ogawa T, et al. Effects of pulmonary rehabilitation in patients with idiopathic pulmonary fibrosis. Respirology 2008; 13(3): 394-399.
9. Holland AE, Hill CJ, Conron M, Munro P, McDonald CF. Short term improvement in exercise capacity and symptoms following exercise training in interstitial lung disease. Thorax 2008; 63(6): 549-554.
10. Oga T, Nishimura K, Tsukino M, Hajiro T, Ikeda A, Izumi T. The effects of oxitropium bromide on exercise performance in patients with stable chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000; 161 (6): 1897-1901.
11. O'Donnell DE, Lam M, Webb KA. Measurement of symptoms, lung hyperinflation, and endurance during exercise in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998; 158(5 Pt 1): 1557-1565.
12. Casaburi R, Kukafka D, Cooper CB, Witek TJ Jr, Kesten S. Improvement in exercise tolerance with the combination of tiotropium and pulmonary rehabilitation in patients with COPD. Chest 2005; 127(3): 809-817.
13. American Thoracic Society, European Respiratory Society. American Thoracic Society/European Respiratory Society international multidisciplinary consensus classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med 2002; 165(2): 277-304.
14. American Thoracic Society. Standardization of spirometry: 1994 update. Am J Respir Crit Care Med 1995; 152(3): 1107-1136.
15. Japan Society of Chest Diseases. [The predicted values of pulmonary function testing in Japanese]. Jpn J Thorac Dis 2001; 39: 1-17 (Appendix). Article in Japanese.
16. Watanabe F, Taniguchi H, Sakamoto K, Kondoh Y, Kimura T, Kataoka K, et al. Quadriceps weakness contributes to exercise capacity in nonspecific interstitial pneumonia. Respir Med 2013; 107(4): 622-628.
17. Black LF, Hyatt RE. Maximal respiratory pressures: normal values and relationships to age and sex. Am Rev Respir Dis 1969; 99(5): 698-702.
18. American Thoracic Society, American College of Chest Physicians. ATS/ACCP statement on cardiopulmonary exercise testing. Am J Respir Crit Care Med 2003; 167(2): 211-277.
19. ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med 2002; 166(1): 111-117.
20. Holland AE, Hill CJ, Conron M, Munro P, McDonald CF. Small changes in six-minute walk distance are important in diffuse parenchymal lung disease Respir Med 2009; 103: 1430-1435.
21. Singh SJ, Morgan MD, Scott S, Walters D, Hardman AE. Development of a shuttle walking test of disability in patients with chronic airways obstruction. Thorax 1992; 47(12): 1019-1024.
22. Jones PW, Harding G, Wiklund I, Berry P, Tabberer M, Yu R, Leidy NK. Tests of the responsiveness of the COPD assessment test following acute exacerbation and pulmonary rehabilitation. Chest 2012; 142(1): 134-140.
23. Cohen J. Statistical power analysis for the behavioural sciences, 2nd edition. New York: Lawrence Erlbaum Associates; 1988.
24. Arizono S, Taniguchi H, Nishiyama O, Kondoh Y, Kimura T, Kataoka K, et al. Improvements in quadriceps force and work efficiency are related to improvements in endurance capacity following pulmonary rehabilitation in COPD patients. Intern Med 2011; 50(21): 2533-2539.
25. Kozu R, Senjyu H, Jenkins SC, Mukae H, Sakamoto N, Kohno S. Differences in response to pulmonary rehabilitation in idiopathic pulmonary fibrosis and chronic obstructive pulmonary disease. Respiration 2011; 81(3): 196-205.
26. Swinburn CR, Wakefield JM, Jones PW. Performance, ventilation, and oxygen consumption in three different types of exercise test in patients with chronic obstructive lung disease. Thorax 1985: 40(8): 581-586.
27. Luxton N, Alison JA, Wu J, Mackey MG. Relationship between field walking tests and incremental cycle ergometry in COPD. Respirol-ogy 2008; 13(6): 856-862.
28. Porszasz J, Emtner M, Goto S, Somfay A, Whipp BJ, Casaburi R. Exercise training decreases ventilatory requirements and exercise-induced hyperinflation at submaximal intensities in patients with COPD. Chest 2005; 128(4): 2025-2034.
29. Akkerman M, van Brussel M, Hulzebos E, Vanhees L, Helders P, Takken T. The Oxygen Uptake Efficiency Slope: what do we know? J Cardiopulm Rehabil Prev 2010; 30: 357-373.
30. Mainguy V, Maltais F, Saey D, Gagnon P, Martel S, Simon M. Provencher S. Peripheral muscle dysfunction in idiopathic pulmonary arterial hypertension. Thorax 2010; 65(2): 113-117.